MaxCyte Inc on Wednesday said it has signed a strategic platform licence with TG Therapeutics Inc to develop its autoimmune cell therapy.

The Rockville, Maryland-based provider of cell engineering platform technologies said it will receive annual licensing fees and program-related revenue under the agreement.

TG Therapeutics gains research, clinical and commercial rights to use MaxCyte’s flow electroporation technology and Expert platform to support the development of azer-cel, a cell therapy programme to treat autoimmune diseases.

Chief Executive Officer Maher Masoud said: ‘By leveraging our commercially validated cell-engineering platform and optimized T cell manufacturing workflow, TG Therapeutics is advancing toward their phase 1 clinical trial for the application of azer-cel in progressive forms of MS... With our new partnership, we will continue to support the development of azer-cel to expand the application to autoimmune diseases.’

Shares in MaxCyte were up 0.7% to 342.50 pence in London on Wednesday morning.

Copyright 2025 Alliance News Ltd. All Rights Reserved.